About 16 million American adults and 10 million children live with atopic dermatitis, and it is one of the most treatable chronic skin conditions in medicine. What determines how well someone does is rarely the strength of the steroid — it is whether the skin barrier is being repaired consistently, and whether the treatment ladder is being followed in the right order.
The skin is not a passive covering. It is an active barrier — a tightly organized wall of cells and lipids that keeps water in and keeps allergens, irritants, and microbes out. In atopic dermatitis, that wall is structurally weaker than it should be. Two things go wrong at the same time, and they reinforce each other.
First, the barrier itself is compromised. The outer layer of skin — the stratum corneum — is normally built like brick and mortar: flat, tightly packed cells (corneocytes) held together by a lipid matrix rich in ceramides. In atopic dermatitis, ceramide levels are reduced, the cells are smaller and less well organized, and the structural protein filaggrin is often deficient. Mutations in the FLG gene, which codes for filaggrin, are found in up to 30 percent of eczema patients in some populations — making the barrier less effective at retaining water and blocking irritants.
Second, the immune system is over-reactive. When allergens and irritants slip through the compromised barrier, they encounter immune cells that are already primed to react. The result is a self-sustaining cycle of type 2 inflammation, driven by cytokines like IL-4, IL-13, and IL-31. The inflammation further damages the barrier, which allows more allergens through, which fuels more inflammation.
This is why emollients matter as much as medication. Moisturizers repair the barrier; steroids and other medications reduce the inflammation. Neither alone is enough. A patient using only a steroid without consistent emollient use often sees a flare improve and then return within days — because the barrier underneath was never repaired.
A third factor is the skin microbiome. Over 90 percent of eczema patients are colonized with Staphylococcus aureus, which produces toxins that further inflame the skin and disrupt the barrier. This is one reason secondary bacterial infection is so common during a flare.
Many children who develop atopic dermatitis go on to develop other atopic conditions in a recognizable pattern. The "atopic march" describes this progression — but it is not inevitable, and modern treatment may reduce the risk of progression.
Eczema often begins on the cheeks, scalp, and extensor surfaces in infancy.
Food sensitization develops in a subset — commonly egg, milk, peanut, or wheat. Often detected via allergy testing after a reaction.
Wheezing and airway hyperresponsiveness develop in roughly 30% of children with eczema — more often in those with severe or persistent disease.
Seasonal or year-round nasal symptoms typically appear last, completing the classic sequence in those who progress.
The distribution of lesions is one of the most useful clues in diagnosis. Infants and young children have a different pattern from older children and adults.
Cheeks, scalp, and outer surfaces of arms and legs. The trunk may be involved; the diaper area is usually spared because of moisture.
Antecubital and popliteal fossae (elbow and knee creases), neck, wrists, hands, and ankles. Hands are commonly affected in adults, especially occupational eczema.
Atopic dermatitis is managed with a stepwise approach. Each step adds to the one below — it does not replace it. Patients who move up the ladder without consistent emollient use at the base often cycle through increasingly strong medications without lasting control.
Fragrance-free moisturizers applied twice daily, and immediately after bathing while the skin is still damp. Emollients do not treat inflammation — they repair the barrier so that inflammation has less to feed on. Ointments and thick creams are more effective than lotions.
Consistent emollient use has been shown to reduce the need for topical steroids in many patients, and may reduce the frequency of flares. It is not optional — it is the base of the ladder.
Available in seven potency classes. The choice depends on the site: low potency on face, neck, and skin folds; medium or high potency on the trunk and limbs. Applied to active lesions only — not to unaffected skin — typically once or twice daily for 5 to 14 days.
Concerns about skin thinning are real but largely reflect misuse — high-potency steroids on thin skin for extended periods. Used correctly, they are safe and remain the standard first-line anti-inflammatory.
Tacrolimus ointment and pimecrolimus cream do not cause skin thinning, which makes them particularly useful for the face, eyelids, neck, and skin folds. They are also used for maintenance therapy — applied two to three times per week to previously affected skin to prevent flares.
Common side effects include transient burning or stinging at the site, which usually fades after the first week. FDA boxed warning for malignancy was removed in 2025 after long-term safety data did not confirm earlier concerns.
When topicals are insufficient, several systemic options exist. Dupilumab and tralokinumab are monoclonal antibodies that block IL-4 and IL-13 signaling. Oral JAK inhibitors (upadacitinib, abrocitinib) act faster but carry boxed warnings for serious infections, thrombosis, and malignancy. Traditional immunosuppressants (cyclosporine, methotrexate, azathioprine) remain options in specific cases.
Biologics are given as injections every two to four weeks and produce substantial improvement in itch and skin clearance. They are expensive but increasingly covered by insurance for documented moderate-to-severe disease.
Bleach baths (dilute sodium hypochlorite) reduce staph colonization and are recommended for patients with frequent infections. Wet-wrap therapy intensifies topical treatment for severe flares. Antihistamines — first-generation, at bedtime — may help with sleep disruption from itch, though their effect on itch itself is modest.
For patients with confirmed food allergy, allergen avoidance in consultation with an allergist. Routine food elimination without confirmed allergy is not recommended — it rarely improves eczema and risks nutritional deficiency.
Triggers are personal, but the categories are consistent. Identifying yours is the second half of control after consistent barrier repair and anti-inflammatory treatment.
Winter heating and low-humidity climates pull moisture from the skin. A home humidifier and more frequent emollient use in winter make a measurable difference. Short, lukewarm showers — not hot — help preserve the barrier.
Fragrances, essential oils, harsh soaps, detergents, and preservatives in skin products. Patients should use fragrance-free, dye-free products and avoid antibacterial soaps unless medically necessary.
Stress does not cause eczema, but it worsens it — through cortisol dysregulation, immune activation, and reduced barrier recovery. Poor sleep is both a consequence of itch and a driver of flares.
Exercise, hot weather, and heavy clothing trap sweat against the skin, which is a known irritant. Showering and reapplying emollient after sweating reduces flares in active patients.
Dust mites, pet dander, pollen, and mold. Environmental control — mattress covers, HEPA filters, washing bedding weekly in hot water — can reduce exposure in sensitized patients.
Staph colonization is present in over 90% of patients. Active infection triggers flares and requires treatment — topical mupirocin for mild cases, oral antibiotics for more extensive involvement.
Several eczema medications are available as low-cost generics in the United States. Hydrocortisone, triamcinolone, mometasone, betamethasone, tacrolimus, and pimecrolimus are all available as generics and priced well below their original brand versions. Emollients are over the counter and widely accessible. Antihistamines like hydroxyzine are cheap generics.
What matters in practice: the same generic topical steroid can cost five to ten times more at one licensed pharmacy than another. A tube of triamcinolone 0.1% cream — the workhorse of eczema treatment — can vary substantially depending on the seller. A live prescription price comparison shows the current range in about two minutes, and the same logic applies to every generic on a patient's list. For a first-time online refill, the process is documented step by step in this how to order prescriptions online guide — prescription first, licensed seller second, small first order third.
The bigger cost challenge in eczema is biologics. Dupilumab, tralokinumab, and lebrikizumab are brand-only, injected every two to four weeks, and can cost thousands of dollars per month without insurance. The manufacturers run patient assistance and copay programs that bring the cost down substantially for commercially insured patients, and many state Medicaid programs cover them. If the medication is unaffordable, tell the prescriber — there is almost always a program available, or a step-down option that fits the budget.
Before filling from any seller — online or local — verify them. A working VIPPS seal that resolves to a live NABP record, a real U.S. street address, and a prescription requirement that cannot be waived. A transparency page like this one about Metformin4You is a reasonable example of the standard to expect.
Most eczema medication is available as a low-cost generic, and the same tube or tablet can cost several times more at one licensed pharmacy than another. A two-minute comparison across licensed U.S. sellers is a useful habit to build. Begin with the current Metformin price comparison as a live demonstration of how wide the spread runs.
Open the price comparison